Table of Contents

• Introduction
• What is B/PHUKET/3073/2013-LIKE VIRUS?
• Role in Influenza Vaccines
• Clinical Trials and Research
• Safety and Effectiveness
• Conclusion

Introduction

Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses. To protect against this disease, scientists develop vaccines that target specific strains of the virus. One such component used in many influenza vaccines is the B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE). This article will explore what this virus is, its role in vaccines, and the ongoing research involving it.^[1]

What is B/PHUKET/3073/2013-LIKE VIRUS?

The B/PHUKET/3073/2013-LIKE VIRUS is a strain of influenza B virus. It was first isolated in Phuket, Thailand in 2013, hence its name. This virus belongs to the B/Yamagata lineage, which is one of the two main lineages of influenza B viruses that commonly circulate among humans.^[1]

In vaccine development, this virus is often referred to as a “wild type” strain. This means it’s a naturally occurring form of the virus, as opposed to a modified or laboratory-created version. The term “LIKE” in its name indicates that the vaccine may contain either this exact strain or a very similar one that produces the same immune response.

Role in Influenza Vaccines

The B/PHUKET/3073/2013-LIKE VIRUS is a crucial component in many influenza vaccines, particularly in quadrivalent (four-strain) vaccines. These vaccines typically include two influenza A strains and two influenza B strains to provide broader protection against circulating flu viruses.^[1]

When included in a vaccine, this virus strain helps the immune system develop antibodies that can recognize and fight off similar influenza B viruses if the person is exposed to them. This process, known as immunogenicity, is key to how vaccines protect against disease.

Clinical Trials and Research

Several clinical trials have been conducted or are ongoing to study vaccines containing the B/PHUKET/3073/2013-LIKE VIRUS. These studies aim to evaluate the effectiveness, safety, and immune response generated by these vaccines in different populations. For example:

• A Phase 3 randomized trial is comparing a high-dose quadrivalent influenza vaccine (which includes this virus strain) to a standard-dose vaccine in older adults. The study aims to evaluate the relative vaccine effectiveness in reducing hospitalizations for influenza or pneumonia.^[1]
• Another study is investigating the effect of influenza vaccination, including this strain, on preserving beta cell function in patients with early type 1 diabetes.^[2]
• Researchers are also studying the immunogenicity and safety of co-administering an ExPEC9V vaccine with a high-dose quadrivalent influenza vaccine containing this strain in adults aged 65 years or older.^[3]

Safety and Effectiveness

Vaccines containing the B/PHUKET/3073/2013-LIKE VIRUS have generally been found to be safe and effective. However, like all medical treatments, they can have side effects. Common side effects may include:

• Pain, redness, or swelling at the injection site
• Fatigue
• Headache
• Muscle aches
• Fever (less common)

It’s important to note that these side effects are typically mild and short-lived. Serious allergic reactions are rare but can occur. People with severe allergies to eggs or any components of the vaccine should consult their healthcare provider before getting vaccinated.^[1]

Conclusion

The B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE) plays a significant role in many current influenza vaccines. As a component of quadrivalent flu vaccines, it helps provide protection against a common strain of influenza B virus. Ongoing research continues to evaluate its effectiveness in different populations and in combination with other vaccines. While generally safe and effective, as with any medical treatment, it’s important to discuss any concerns or questions with a healthcare provider.